参考文献/References:
[1].王建旗,史旭波,马生,.炎症预测和预防动脉粥样硬化心血管事件的研究进展[J].心血管病学进展,2018,39(5):687-690.
[2].van der Heijden T,Bot I,Kuiper J.The IL-12 cytokine family in cardiovascular diseases[J].Cytokine,2019122:154188.
[3].Posadas-Sánchez R,Vargas-Alarcón G.Innate immunity in coronary disease.The role of interleukin-12 cytokine family in atherosclerosis[J].Rev Invest Clin,2018,70(1):5-17.
[4].Behzadi P,Behzadi E,Ranjbar R.IL-12 family cytokines:general characteristics,pathogenic microorganisms,receptors,and signalling pathways[J].Acta Microbiol Immunol Hung,2016,63(1):1-25.
[5].Liu W,Chang C,Hu H,et al.Interleukin-23:a new atherosclerosis target[J].J Interferon Cytokine Res,2018,38(10):440-444.
[6].Staciwa M,Broncel M.The biological function and significance of IL-35 in the pathogenesis of atherosclerosis[J].Pol Merkur Lekarski,2018,44(262):161-164.
[7].Wang X,Wei Y,Xiao H,et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in lupus-like mice[J]. Eur J Immunol,2016,46(6):1343-1350.
[8].J??skel?inen AE,Sepp?l? S,Kakko T,et al.Systemic treatment with neuropeptide Y receptor Y1-antagonist enhances atherosclerosis and stimulates IL-12 expression in ApoE deficient mice[J].Neuropeptides,2013,47(2):67-73.
[9].Zykov MV,Barbarash OL,Kashtalap VV,et al.Interleukin-12 serum level has prognostic value in patients with ST-segment elevation myocardial infarction[J].Heart Lung,2016,45(4):336-340.
[10].Yong K,Dogra G,Boudville N,et al.Interleukin-12 is associated with arterial stiffness in healthy individuals[J].Am J Hypertens,2013,26(2):159-162.
[11].Opstad TB,Arnesen H,Pettersen AA,et al.Combined elevated levels of the proinflammatory cytokines IL-18 and IL-12 are associated with clinical eventsin patients with coronary artery disease:an observational study[J].Metab Syndr Relat Disord,2016,14(5):242-248.
[12].Bilik MZ,Kaplan?,Polat N,et al.Serum levels of IL-17 and IL-23 in patients with rheumatic mitral stenosis[J].Medicine,2016,95(18):e3562.
[13].Subramanian M,Thorp E,Tabas I.Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis:promotion of macrophage apoptosisand plaque necrosis through IL-23 signaling[J].Circ Res,2015,116(2):e13-e24.
[14].Abbas A,Gregersen I,Holm S,et al.Interleukin 23 levels are increased in carotid atherosclerosis:possible role for the interleukin 23/interleukin 17 axis[J].Stroke,2015,46(3):793-799.
[15].Grufman H,Yndigegn T,Gon?alves I,et al.Elevated IL-27 in patients with acute coronary syndrome is associated with adverse ventricular remodeling and increased risk of recurrent myocardial infarction and cardiovascular death[J].Cytokine,2019,122:154208.
[16].Si F,Wu Y,Gao F,et al.Relationship between IL-27 and coronary arterial lesions in children with Kawasaki disease[J].Clin Exp Med,2017,17(4):451-457.
[17].Miura K,Saita E,Suzuki-Sugihara N,et al.Plasma interleukin-27 levels in patients with coronary artery disease[J].Medicine,2017,96(43):e8260.
[18].Gregersen I,Sandanger ?,Askevold ET,et al.Interleukin 27 is increased in carotid atherosclerosis and promotes NLRP3 inflammasome activation[J].PLoS One,2017,12(11):e0188387.
[19].Luo Y,Liu F,Liu H,et al.Elevated serum IL-39 in patients with ST-segment elevation myocardial infarction was related with left ventricular systolic dysfunction[J].Biomark Med,2017,11(6):419-426.
[20].Huang Y,Hu H,Liu L,et al.Interleukin-12p35 deficiency reverses the Th1/Th2 imbalance,aggravates the Th17/Treg imbalance,and ameliorates atherosclerosis in ApoE-/-mice[J].Mediators Inflamm,2019,2019:3152040.
[21].Rasa F,Naderi N,Eftekhar E,et al.Vitamin D status in coronary artery disease:association with IL-35 and TGF-β1 and disease severity[J].Endocr Metab Immune Disord Drug Targets,2018,18(5):522-529.
[22].Su Y,Feng S,Luo L,et al.Association between IL-35 and coronary arterial lesions in children with Kawasaki disease[J].Clin Exp Med,2019,19(1):87-92.
[23].Zhu Z,Zhang Y,Ye J,et al.IL-35 promoted STAT3 phosphorylation and IL-10production in B cells,but its production was reduced in patients with coronary artery diseases[J].Hum Immunol,2018,79(12):869-875.
[24].Hirase T,Hara H,Miyazaki Y,et al. Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice[J]. AJP Heart Circ Physiol,2013, 305(3):H420-H429.
[25].Ma MC,Wang BW,Yeh TP,et al. Interleukin-27, a novel cytokine induced by ischemia-reperfusion injury in rat hearts,mediates cardioprotective effects via the gp130/STAT3 pathway[J]. Basic Res Cardiol,2015,110(3):22.
[26].Flores RR,Kim E,Zhou L,et al.IL-Y,a synthetic member of the IL-12 cytokine family,suppresses the development of type 1 diabetes in NOD mice[J].Eur J Immunol,2015,45(11):3114-3125.
[27].van Vollenhoven RF,Hahn BH,Tsokos GC,et al.Efficacy and safety of ustekinumab,an IL-12 and IL-23 inhibitor,in patients with active systemic lupus erythematosus:results of a multicentre,double-blind,phase 2,randomised,controlled study[J].Lancet,2018,392(10155):1330-1339.
[28].Moschen AR,Tilg H,Raine T.IL-12,IL-23 and IL-17 in IBD:immunobiology and therapeutic targeting[J].Nat Rev Gastroenterol Hepatol,2019,16(3):185-196.
相似文献/References:
[1]程晓艺,寇秀玲,黄明刚,等.颈动脉斑块与冠状动脉粥样硬化相关性影像学分析[J].心血管病学进展,2019,(6):960.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.030]
CHENG Xiaoyi,KOU Xiuling,HUANG Minggang,et al.Imaging Analysis of Carotid Plaque and Coronary Artery Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):960.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.030]
[2]梁春晓 李爽 刘莹 余建群.不同区域的心包脂肪容积与心血管危险因素及冠状动脉粥样硬化的关系[J].心血管病学进展,2020,(8):873.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
LIANG Chunxiao,LI Shuang,LIU Ying,et al.Epicardial, Paracardial and Pericardial Fat Volume by CCTA: Relationship with Cardiovascular Risk Factors and Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2020,(5):873.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
[3]李爽 梁春晓 方鑫 刘莹 余建群.心包内脂肪容积对糖尿病及非糖尿病患者冠状动脉粥样硬化影响的CT评价[J].心血管病学进展,2020,(9):972.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.021]
LI Shuang,LIANG Chunxiao,FANG Xin,et al.Effect of Epicardial Adipose Tissue Volume by CCTA on Coronary Atherosclerosis in Patients with or without Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(5):972.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.021]
[4]王 西,王 萍.大动脉炎加速冠状动脉粥样硬化机制的研究进展[J].心血管病学进展,2022,(2):154.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.015]
WANG XiWANG Ping.Mechanism of Accelerated Atherosclerosis in Takayasu Arteritis[J].Advances in Cardiovascular Diseases,2022,(5):154.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.015]
[5]谭思华 周晓莉.非酒精性脂肪肝与冠状动脉粥样硬化及炎症的研究进展[J].心血管病学进展,2023,(5):439.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.013]
TAN Sihua,ZHOU Xiaoli.Association of Non-Alcoholic Fatty Liver Disease with Coronary Atherosclerosis and Inflammation[J].Advances in Cardiovascular Diseases,2023,(5):439.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.013]
[6]韩冰 来春林.黑色素瘤缺乏因子2炎症小体在心血管疾病中的研究进展[J].心血管病学进展,2023,(11):986.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.007]
HAN Bing,LAI Chunlin.Absent In Melanoma 2 Inflammasome in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(5):986.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.007]